- Home
- MLTX vs PRME Comparison
MLTX vs PRME Comparison
Compare MLTX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- PRME
- Stock Information
- Founded
- MLTX 2021
- PRME 2019
- Country
- MLTX Switzerland
- PRME United States
- Employees
- MLTX N/A
- PRME N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- MLTX Health Care
- PRME Health Care
- Exchange
- MLTX Nasdaq
- PRME Nasdaq
- Market Cap
- MLTX 595.6M
- PRME 693.5M
- IPO Year
- MLTX N/A
- PRME 2022
- Fundamental
- Price
- MLTX $9.82
- PRME $4.98
- Analyst Decision
- MLTX Buy
- PRME Buy
- Analyst Count
- MLTX 9
- PRME 6
- Target Price
- MLTX $37.63
- PRME $8.88
- AVG Volume (30 Days)
- MLTX 12.2M
- PRME 4.1M
- Earning Date
- MLTX 11-07-2025
- PRME 11-11-2025
- Dividend Yield
- MLTX N/A
- PRME N/A
- EPS Growth
- MLTX N/A
- PRME N/A
- EPS
- MLTX N/A
- PRME N/A
- Revenue
- MLTX N/A
- PRME $4,961,000.00
- Revenue This Year
- MLTX N/A
- PRME $179.58
- Revenue Next Year
- MLTX N/A
- PRME N/A
- P/E Ratio
- MLTX N/A
- PRME N/A
- Revenue Growth
- MLTX N/A
- PRME 739.42
- 52 Week Low
- MLTX $5.95
- PRME $1.11
- 52 Week High
- MLTX $62.75
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- MLTX 27.40
- PRME 45.28
- Support Level
- MLTX $8.92
- PRME $4.93
- Resistance Level
- MLTX $9.47
- PRME $5.55
- Average True Range (ATR)
- MLTX 0.62
- PRME 0.60
- MACD
- MLTX 1.54
- PRME -0.18
- Stochastic Oscillator
- MLTX 47.44
- PRME 5.08
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.